The Role of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease

References

• . Qaseem A, Wilt TJ, Weinberger SE, . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179–191
   PubMed Web of Science ®Google Scholar
• . Global strategies for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD) 2013 update. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed May 17, 2013
   Google Scholar
• . Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004;117( Suppl 12A):24S–32S
   PubMed Web of Science ®Google Scholar
• . Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2012
   Google Scholar
• . SPIRIVA® HandiHaler® Capsules for Respiratory Inhalation (tiotropium bromide inhalation powder) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2013
   Google Scholar
• . Tudorza Pressair (aclidinium bromide inhalation powder) [package insert]. St. Louis, MO: Forest Pharmaceuticals; 2012
   Google Scholar
• . Forest Pharmaceuticals, Inc. Tudorza Pressair press release: Forest Laboratories and Almirall announce FDA approval of Tudorza™ Pressair™ for the long-term maintenance treatment of COPD. Forest Laboratories, Inc. Media Release July 23, 2012. http://news.frx.com/press-release/corporate-news/forest-laboratories-and-almirall-announce-fda-approval-tudorza-pressair. Accessed January 12, 2014)
   Google Scholar
• . EIN News. PR Newswire. Eklira®/Bretaris® Genuair7reg; (aclidinium bromide) approved in Europe for the maintenance treatment of chronic obstructive pulmonary disease (COPD). July 24, 2012. Barcelona, Spain. http://www.prnewswire.co.uk/news-releases/eklirabretaris-genuair-aclidinium-bromide-approved-in-europe-for-the-maintenance-treatment-of-chronic-obstructive-pulmonary-disease-copd-163619726.html. Accessed January 14, 2014)
   Google Scholar
• . Campbell SC. Clinical aspects of inhaled anticholinergic therapy. Respir Care. 2000;45(7):864–867
   PubMedGoogle Scholar
• . Brodde OE, Bruk H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol. 2001;96(6):528–538
   PubMed Web of Science ®Google Scholar
• . Gavaldà A, Miralpeix M, Ramos I, . Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009;331(2):740–751
   PubMed Web of Science ®Google Scholar
• . Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J COPD. 2011;6:457–466
   Google Scholar
• . Alagha K, Bourdin A, Tummino C, Chanez P. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Ther Adv Respir Dis. 2011;5(1):19–28
   PubMedGoogle Scholar
• . Jansat JM, Lamarca E, Gil G, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009;47(7):460–468
   PubMed Web of Science ®Google Scholar
• . Jansat JM, Lamarca R, de Miguel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol. 2009;49(10):1239–1246
   PubMed Web of Science ®Google Scholar
• . Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM. Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: a phase I, open-label, single-dose clinical trial. Clin Ther. 2010;32(10):1798–1812
   PubMed Web of Science ®Google Scholar
• . Chanez P, Burge PS, Dahl R, . Aclidinium bromide provides long-acting bronchodilation in patients with COPD. Pulm Pharmacol Ther. 2010;23(1):15–21
   PubMed Web of Science ®Google Scholar
• . Vestbo J, Vogelmeier C, Creemers J, Falgues M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD. 2010;7(5):331–336
   PubMedGoogle Scholar
• . Fuhr R, Magnussen H, Sarem K, . Efficacy of aclidinium bromide 400 μg BID compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest. 2012;141(3):745–752
   PubMed Web of Science ®Google Scholar
• . Singh D, Magnussen H, Kirsten A, . A randomized, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther. 2012;25(3):248–253
   PubMed Web of Science ®Google Scholar
• . Maltais F, Celli B, Casaburi R, . Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011;105(4):580–587
   PubMed Web of Science ®Google Scholar
• . Maltais F, Hamilton A, Marciniuk D, . Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178
   PubMed Web of Science ®Google Scholar
• . O'Donnell DE, Fluge T, Gerken F, . Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840
   PubMed Web of Science ®Google Scholar
• . O'Donnell DE, Sciurba F, Celli B, . Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130(3):647–656
   PubMed Web of Science ®Google Scholar
• . Jones PW, Rennard SI, Agusti A, . Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12(1):55
   PubMed Web of Science ®Google Scholar
• . Tashkin DP, Celli B, Senn S, . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554
   PubMed Web of Science ®Google Scholar
• . Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Gil EG, Caracta CF; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9(2):90–101
   PubMedGoogle Scholar
• . D'Urzo A, Kerwin E, Rennard S, . One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD. 2013;10(4): 500–510
   PubMedGoogle Scholar
• . Rennard SI, Scanton PD, Ferguson GT, . ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Invest. 2013;33(12):893–904
   PubMed Web of Science ®Google Scholar
• . Data on file. Clinical study report no. LAS-MD-38B. Forest Research Institute, Jersey City, NJ, July 16, 2013
   Google Scholar
• . Jones PW, Singh D, Bateman ED, . Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study. Eur Respir J. 2012;40(4):830–836
   PubMed Web of Science ®Google Scholar
• . Gelb AF, Tashkin DP, Make BJ, . Long-term safety and efficacy of twice daily aclidinium bromide in patients with COPD. Respir Med. 2013;107(12):1957–1965
   PubMed Web of Science ®Google Scholar
• . Beier J, Kirsten, AM, Mróz R, . Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013;10(4):511–522
   PubMedGoogle Scholar
• . Almirall SA; Forest Laboratories. Effect and safety of aclidinium bromide 400 μg BID (twice a day) compared to placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01471171?term=aclidinium&rank=15. Identifier: NCT01471171
   Google Scholar
• . Daewoong Pharmaceutical Co. LTD. Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01636401?term=aclidinium&rank=14. Identifier: NCT01636401
   Google Scholar
• . Almirall SA; Forest Laboratories. Clinical trial to assess rate of onset of bronchodilator action in severe stable chronic obstructive pulmonary disease (COPD) patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/study/NCT00435760?term=NCT00435760&rank=1. Identifier: NCT00435760
   Google Scholar
• . Almirall SA; Forest Laboratories. Safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (LAC). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT01437540?term=aclidinium&rank=14. Identifier: NCT01437540
   Google Scholar
• . Almirall SA; Forest Laboratories. long-term efficacy and safety of aclidinium/formoterol fixed-dose combination. In: ClinicalTrials.gov[Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01462942?term=aclidinium&rank=10. Identifier: NCT01462942
   Google Scholar
• . Almirall SA; Forest Laboratories. Efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) (LAC). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01437397?term=aclidinium&rank=8. Identifier: NCT01437397
   Google Scholar
• . Almirall SA; Forest Laboratories. Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (COPD). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01572792?term=aclidinium&rank=2. Identifier: NCT01572792
   Google Scholar
• . Almirall SA. Study of aclidinium bromide/formoterol fumarate compared with salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/record/NCT01908140?term=NCT01908140&rank=1. Identifier: NCT01908140
   Google Scholar
• . Forest Laboratories. Evaluate the effect of aclidinium bromide on long-term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). In: ClinicalTrials. gov [Internet]. Bethesda, MD: National Library of Medicine (US). January 10, 2014. http://clinicaltrials.gov/ct2/show/NCT01966107?term=NCT01966107&rank=1. Identifier: NCT01966107
   Google Scholar
• . Karabis A, Lindner L, Mocarski M, Huisman E, Greening A. Comparative efficacy of aclidinium versus gycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Int J COPD. 2013;8:405–423
   Google Scholar
• . Ortiz S, Flach S, Caracta C, Gil EG, Jansat JM. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants. J Clin Pharmacol. 2012;52(6):819–827
   PubMed Web of Science ®Google Scholar
• . Lasseter K, Dilzer S, Jansat JM, Gil EG, Caracta CF, Ortiz S. Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers. Pulm Pharmacol Ther. 2012;25(2):193–199
   PubMed Web of Science ®Google Scholar
• . de la Motte S, Beier J, Schmid K, Pascual S, Jansat JM, Gil EG. Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther. 2012;50(6):403–412
   PubMed Web of Science ®Google Scholar
• . Lasseter KC, Aubets J, Cheucos F, Gil EG. Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects. J Clin Pharmacol. 2011;51(6):923–932
   PubMed Web of Science ®Google Scholar
• . Alberti J, Martinet A, Sentellas S, Salva M. Identification of the human enzymatic hydrolysis of aclidinium bromid. Drug Metab Dispos. 2010;38(7):1202–1210
   PubMed Web of Science ®Google Scholar
• . Joos GF, Schelfhout VJ, Pauwels RA, . Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist in COPD patients. Respir Med. 2010;104(6):865–872
   PubMed Web of Science ®Google Scholar
• . Magnussen H, Watz H, Zimmermann I, . Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD. Respir Med. 2009;103(12):1832–1837
   PubMed Web of Science ®Google Scholar
• . Almirall International Pharmaceutical Company (Corporate website). Genuair®: A new technologically advanced dry powder inhaler. DPI Almirall: Genuair®. http://www.almirallsofotec.com/en/genuair_dpiIntro.html. Accessed October 7, 2012
   Google Scholar
• . Aclidinium. In: Lexi-Comp Online. Hudson, OH: Lexi-Comp, Inc. Updated periodically. Accessed January 12, 2014
   Google Scholar
• . Ipratropium. In: Lexi-Comp Online. Hudson, OH: Lexi-Comp, Inc. Updated periodically. Accessed January 12, 2014
   Google Scholar
• . Tiotropium. In: Lexi-Comp Online. Hudson, OH: Lexi-Comp, Inc. Updated periodically. Accessed January 12, 2014
   Google Scholar
• . Flynn RA. Anticholinergic treatment in airways diseases. Adv Ther. 2009;26(10):908–919
   PubMed Web of Science ®Google Scholar
• . Wilt TJ, Niewoehner D, MacDonald R, Kane R. Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med. 2007;147(9):639–653
   PubMed Web of Science ®Google Scholar
• . Yohannes AM, Connolly MJ, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013;8:117–125
   PubMed Web of Science ®Google Scholar